• Product nameAnti-NFkB p100 antibody
    See all NFkB p100 primary antibodies
  • Description
    Rabbit polyclonal to NFkB p100
  • SpecificityThis antibody detects sites on p100 only. Sometimes there is a 52kDa band on WB; this is not p52. There is a cleavage site on the NFKB2 (Swiss-Prot No.: Q00653). The cleavage site is between 454 and 455 (cleavage when cotranslationally processed). The antibody can interact with the C-half sometimes. The MW. of C-half is near 52Kd.
  • Tested applicationsSuitable for: ELISA, WB, IP, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human NFkB p100. Taken from around the phosphorylation site S865 Immunogen range is 833 to 882.
    Database link: Q00653

  • Positive control
    • WB: extract of ovary cancer cells. IHC: and breast carcinoma tissue.


Associated products


Our Abpromise guarantee covers the use of ab31432 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/20000.
WB 1/500 - 1/1000. Detects a band of approximately 52, 100 kDa (predicted molecular weight: 54 , 96 kDa).
IP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration.


  • RelevanceNF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.
  • Cellular localizationCytoplasmic and Nuclear
  • Database links
  • Alternative names
    • CVID10 antibody
    • DNA binding factor KBF2 antibody
    • H2TF1 antibody
    • Lymphocyte translocation chromosome 10 protein antibody
    • LYT 10 antibody
    • NF kB2 antibody
    • NFKB p52/p100 subunit antibody
    • Nuclear factor Kappa B subunit 2 antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100) antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody
    • Oncogene Lyt 10 antibody
    • p100 antibody
    • Transcription factor NFKB2 antibody
    see all

Anti-NFkB p100 antibody images

  • ab31432, at a dilution of 1/50-1/100, staining NFkB p100 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
    Left image: Untreated.
    Right image: The same antibody preincubated with synthesized peptide.

References for Anti-NFkB p100 antibody (ab31432)

This product has been referenced in:
  • Alameda JP  et al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene : (2010). WB ; Human . Read more (PubMed: 20838385) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab31432.
Please use the links above to contact us or submit feedback about this product.